Eli Lilly and Company (LLY)
Lilly's Mounjaro helps improve blood sugar control in children in late-stage trial
Eli Lilly's Mounjaro helped children and adolescents aged 10 to 17 years with type 2 diabetes manage their blood sugar better and lose weight, according to trial results presented at a medical meeting on Wednesday.
LLY's $5B Virginia Plant Plan: Will U.S. Manufacturing Shift Pay Off?
Eli Lilly will invest $5B in a new Virginia plant to make cancer drugs, creating 650 jobs amid Trump's tariff push.
Why the Market Dipped But Eli Lilly (LLY) Gained Today
Eli Lilly (LLY) concluded the recent trading session at $763.57, signifying a +2.06% move from its prior day's close.
Lilly CEO: U.K. has gone from biopharma leader to laggard
Lilly CEO Dave Ricks explains why pricing dynamics in the U.K. make it a very unattractive place for Lilly to invest.
Eli Lilly to build $5 billion Virginia facility to boost production of targeted cancer drugs, other treatments
Eli Lilly on Tuesday said it will spend $5 billion to build a manufacturing facility in Goochland County, Virginia, to boost production capacity for targeted cancer drugs and other treatments. The plant is the company's first of four planned U.S. manufacturing sites, which will begin making medicines within five years.
Oxford Industries says new Lilly Pulitzer offerings are winning over shoppers, but its Tommy Bahama line is lagging
Resort-style clothing maker Oxford Industries Inc. on Wednesday offered up mixed second-quarter results and third-quarter expectations, and said that while new Lilly Pulitzer offerings were attracting shoppers, its Tommy Bahama line wasn't.
LLY's Phase III Study on Jaypirca in Front-Line Leukemia Meets Goal
Lilly's Jaypirca shows a strong survival benefit over chemoimmunotherapy in treatment-naive CLL/SLL, boosting its potential in front-line use.
Will LLY's Oncology Portfolio Provide Key Diversification Benefits?
Eli Lilly's oncology portfolio, led by Verzenio and Jaypirca, is adding diversification to its cardiometabolic-driven growth story.
Eli Lilly launches platform for AI-enabled drug discovery
Drugmaker Eli Lilly said on Tuesday it is launching an artificial intelligence and machine learning platform that provides biotech companies access to drug discovery models trained on years of Lilly's research data.
Novo Nordisk Vs Eli Lilly: Novo A Clear Winner
Novo Nordisk stands out as the best pharma stock, outperforming Eli Lilly in key areas. Novo's higher profitability, stronger cash flow, and much lower valuation make it a more attractive investment than Lilly. Novo's discount could become a premium, as investors seek to diversify away from US stocks.
Eli Lilly's Stock Fall Is An Opportunity
I am bullish on Eli Lilly, despite recent underperformance and Orforglipron's clinical results falling short of high expectations. Eli Lilly's robust R&D, strong pipeline, and leadership in diabetes, obesity, and oncology underpin its long-term growth prospects. Recent financial results exceeded expectations, with raised guidance and continued market share gains in weight loss therapies, supporting valuation upside.
Eli Lilly's New Drugs Beyond Mounjaro and Zepbound Boost Sales
Eli Lilly's growing lineup beyond Mounjaro and Zepbound, including Omvoh and Jaypirca, is set to fuel revenue growth through 2025.
